Could a simple infusion let celiac patients eat gluten again?

NCT ID NCT05660109

Completed Disease control Sponsor: Topas Therapeutics GmbH Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called TPM502 in 28 adults with celiac disease. The goal was to see if two infusions of TPM502 could safely train the immune system to tolerate gluten, potentially reducing the need for a lifelong gluten-free diet. Participants received either TPM502 or a placebo and underwent gluten challenges to measure immune responses.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TPM502 (a mixture of gluten protein fragments designed to train the immune system to tolerate gluten)
What this could lead to: If it works, this could point toward a treatment that allows people with celiac disease to eat gluten without harm, reducing the need for a strict gluten-free diet.
What could go wrong: This is a small, early-phase trial (28 people) focused on safety and immune markers, not on actual symptom relief. The treatment may not produce meaningful tolerance, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CELIAC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

celiac disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CELIAC DISEASE

Contacts and locations

Locations

CRST Oy

Turku, FI-20520, Finland
Centre for Human Drug Research

Leiden, 2333 ZA, Netherlands
Charite' Hospital

Berlin, 12200, Germany
Clinical Trial Consultants, Uppsala University

Uppsala, 752 37, Sweden
Oslo University Hospital HF - Rikshospitalet

Oslo, 0372, Norway
Royal Adelaide Hospital

Adelaide, 5000, Australia
University Hospital of North-Norway

Tromsø, 9038, Norway
Wesley Research Institute

Brisbane, 4066, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.